FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4324136765> ?p ?o ?g. }

• W4324136765 endingPage "86" @default.
• W4324136765 startingPage "86" @default.
• W4324136765 abstract "86 Background: Treatment options for mHSPC have continued to evolve. While androgen deprivation therapy (ADT) has been the backbone treatment, more recently early use of docetaxel and/or novel androgen receptor inhibitors (nARIs) has demonstrated improved clinical outcomes. This study assessed real-world treatment among mHSPC patients who received at least one line of therapy (LoT). Methods: A retrospective observational study utilizing de-identified health records from five Cancer Treatment Centers of America (CTCA) included patients with metastatic prostate cancer who were treated with ADT, docetaxel or nARIs at CTCA for 6+ months between 1/2015-3/2021. Treatment patterns were observed from first LoT to metastatic castration resistance, death, or lost-to-follow-up until 3/2022. LoT was defined as first to last date of active drug therapy, not including long-term hormone agonists. First LoT was defined as initial regimen with no new drugs added 30+ days after start date. Patient characteristics, proportion and duration of each LoT, and reasons for early discontinuation were gathered using structured data elements and chart abstraction. Results: The characteristics of the 523 patients in this study were as follows: mean (SD) age 62 (8) years, 60% white and 33% black, 53% with commercial insurance, 75% with ECOG 0-1, and 65% with bone metastasis at diagnosis. Median follow-up time was 2.9 years. The most common LoT 1 regimen was either ADT alone or ADT with first generation androgen receptor inhibitors (FGARI) (table below). 46% received a second and 15% received a third LoT. Mean (SD) duration of first and second active LoTs were 12 (11.8) and 10 (11.1) months, respectively. Among the 65% and 78% patients who discontinued therapy in LoT 1 and 2, respectively, the majority discontinued due to progression of disease (35% LoT 1 and 53% LoT 2) followed by patient choice (23% LoT 1 and 18% LoT 2). Conclusions: Despite recommendations from guidelines on early intensification of therapy in mHSPC, in this contemporary cohort we find that most patients received either ADT alone or ADT ± FGARI in LoT 1 while chemotherapy and nARIs were initiated predominantly in later lines. Most patients discontinued LoT 1 due to disease progression which may suggest undertreatment and need for improved outcomes. Further studies are needed to assess the factors associated with non-intensification of treatments. [Table: see text]" @default.
• W4324136765 created "2023-03-15" @default.
• W4324136765 creator A5013645547 @default.
• W4324136765 creator A5019189402 @default.
• W4324136765 creator A5049895506 @default.
• W4324136765 creator A5055853535 @default.
• W4324136765 creator A5058262670 @default.
• W4324136765 creator A5060268370 @default.
• W4324136765 creator A5074330238 @default.
• W4324136765 creator A5085345204 @default.
• W4324136765 creator A5085500530 @default.
• W4324136765 date "2023-02-20" @default.
• W4324136765 modified "2023-09-27" @default.
• W4324136765 title "Utilization of metastatic hormone sensitive prostate cancer (mHSPC) treatment in a community oncology practice setting." @default.
• W4324136765 doi "https://doi.org/10.1200/jco.2023.41.6_suppl.86" @default.
• W4324136765 hasPublicationYear "2023" @default.
• W4324136765 type Work @default.
• W4324136765 citedByCount "0" @default.
• W4324136765 crossrefType "journal-article" @default.
• W4324136765 hasAuthorship W4324136765A5013645547 @default.
• W4324136765 hasAuthorship W4324136765A5019189402 @default.
• W4324136765 hasAuthorship W4324136765A5049895506 @default.
• W4324136765 hasAuthorship W4324136765A5055853535 @default.
• W4324136765 hasAuthorship W4324136765A5058262670 @default.
• W4324136765 hasAuthorship W4324136765A5060268370 @default.
• W4324136765 hasAuthorship W4324136765A5074330238 @default.
• W4324136765 hasAuthorship W4324136765A5085345204 @default.
• W4324136765 hasAuthorship W4324136765A5085500530 @default.
• W4324136765 hasConcept C121608353 @default.
• W4324136765 hasConcept C126322002 @default.
• W4324136765 hasConcept C143998085 @default.
• W4324136765 hasConcept C2775930923 @default.
• W4324136765 hasConcept C2777899217 @default.
• W4324136765 hasConcept C2778715236 @default.
• W4324136765 hasConcept C2780192828 @default.
• W4324136765 hasConcept C2781190966 @default.
• W4324136765 hasConcept C2781413609 @default.
• W4324136765 hasConcept C530470458 @default.
• W4324136765 hasConcept C61367390 @default.
• W4324136765 hasConcept C71924100 @default.
• W4324136765 hasConceptScore W4324136765C121608353 @default.
• W4324136765 hasConceptScore W4324136765C126322002 @default.
• W4324136765 hasConceptScore W4324136765C143998085 @default.
• W4324136765 hasConceptScore W4324136765C2775930923 @default.
• W4324136765 hasConceptScore W4324136765C2777899217 @default.
• W4324136765 hasConceptScore W4324136765C2778715236 @default.
• W4324136765 hasConceptScore W4324136765C2780192828 @default.
• W4324136765 hasConceptScore W4324136765C2781190966 @default.
• W4324136765 hasConceptScore W4324136765C2781413609 @default.
• W4324136765 hasConceptScore W4324136765C530470458 @default.
• W4324136765 hasConceptScore W4324136765C61367390 @default.
• W4324136765 hasConceptScore W4324136765C71924100 @default.
• W4324136765 hasIssue "6_suppl" @default.
• W4324136765 hasLocation W43241367651 @default.
• W4324136765 hasOpenAccess W4324136765 @default.
• W4324136765 hasPrimaryLocation W43241367651 @default.
• W4324136765 hasRelatedWork W2590294003 @default.
• W4324136765 hasRelatedWork W2770702948 @default.
• W4324136765 hasRelatedWork W3023947295 @default.
• W4324136765 hasRelatedWork W3156855168 @default.
• W4324136765 hasRelatedWork W3200282916 @default.
• W4324136765 hasRelatedWork W4205706045 @default.
• W4324136765 hasRelatedWork W4226303148 @default.
• W4324136765 hasRelatedWork W4229076799 @default.
• W4324136765 hasRelatedWork W4295154856 @default.
• W4324136765 hasRelatedWork W4297472852 @default.
• W4324136765 hasVolume "41" @default.
• W4324136765 isParatext "false" @default.
• W4324136765 isRetracted "false" @default.
• W4324136765 workType "article" @default.